Nautilus Biotechnology Inc
(NAUT)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -36,740 | -18,730 | -63,675 | -46,651 | -30,773 |
| Depreciation Amortization | 1,735 | 840 | 3,046 | 2,075 | 1,220 |
| Accounts payable and accrued liabilities | -308 | 94 | 393 | 22 | -199 |
| Other Working Capital | -3,111 | -1,490 | -3,219 | -2,299 | -2,478 |
| Other Operating Activity | 6,701 | 3,020 | 11,744 | 9,042 | 6,157 |
| Operating Cash Flow | $-31,723 | $-16,266 | $-51,711 | $-37,811 | $-26,073 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -1,159 | -647 | -2,442 | -2,029 | -1,155 |
| Purchase Of Investment | -15,694 | 0 | -112,892 | -51,895 | -46,844 |
| Sale Of Investment | 53,500 | 23,000 | 71,599 | 51,249 | 32,249 |
| Investing Cash Flow | $36,647 | $22,353 | $-43,735 | $-2,675 | $-15,750 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 564 | 245 | 368 | 115 | 99 |
| Financing Cash Flow | $564 | $245 | $368 | $115 | $99 |
| Beginning Cash Position | 20,399 | 20,399 | 115,477 | 115,477 | 115,477 |
| End Cash Position | 25,887 | 26,731 | 20,399 | 75,106 | 73,753 |
| Net Cash Flow | $5,488 | $6,332 | $-95,078 | $-40,371 | $-41,724 |
| Free Cash Flow | |||||
| Operating Cash Flow | -31,723 | -16,266 | -51,711 | -37,811 | -26,073 |
| Capital Expenditure | -1,159 | -647 | -2,442 | -2,029 | -1,155 |
| Free Cash Flow | -32,882 | -16,913 | -54,153 | -39,840 | -27,228 |